The CTC offices are currently closed for refurbishment. Access to trial TMFs and patient records will be limited during this period. We will still be able to receive post during this time, but there may be a small delay in responding to this. Our fax lines may also be subject to disruption. Where possible, please direct all correspondence via email to trial-specific email addresses. We appreciate your patience and understanding.

Due to COVID-19 and current government guidance, UCL CTC staff continue to work remotely with limited access to the office. Please continue to email the trial specific mailbox with any urgent queries. For paper CRF trials, please continue to copy and scan CRFs to the trial inboxes (remove all patient identifiers except Trial Number and Initials) until further notice.

 
HCQ trial sees final analysis published
23 October 2020
The HCQ trial, a trial run by the CR UK & UCL Cancer Trials Centre, was a randomised phase 2 trial investigating the additional benefit of hydroxychloroquine (HCQ) to short course radiotherapy (SCRT) in patients aged 70 years and older with high grade gliomas (HGG). The final analysis for the HCQ trial has recently been published in Neuro-Oncology Advances.

The trial recruited between 2013 and 2016 with 54 patients randomised. The study aimed to investigate whether the administration of hydroxychloroquine with short-course radiotherapy to patients with high grade gliomas aged 70 years and older had an effect on one-year survival compared to short-course radiotherapy alone. The trial also looked to assess the toxicity associated with administering hydroxychloroquine with short-course radiotherapy. On the advice of the Independent Data Monitoring Committee, the study stopped recruitment slightly earlier than anticipated due to better than expected outcomes in the control arm.

The main findings from the analysis are:

hydroxychloroquine with short-course radiotherapy did not improve survival compared to radiotherapy alone in elderly patients with glioblastoma
standard doses of hydroxychloroquine may not enhance tumour regression with short-course radiotherapy
there were more grade 3–5 events in the hydroxychloroquine group versus radiotherapy alone without any clear common causation.

Although the trial did not complete recruitment, the results do add useful information regarding the potential use of authophagy inhibition in glioma and other solid tumours.

The full analysis can be found on the Neuro-Oncology Advances website.
Contact Us
Cancer Research UK & UCL Cancer Trials Centre
University College London
90 Tottenham Court Road
London
W1T 4TJ

View map
Email:
ctc.enquiries@ucl.ac.uk
Telephone:
+44 (0)20 7679 9898 (General CTC Enquiries)
Fax:
020 7679 9899
University College London, Gower Street, London, WC1E 6BT +44 (0)20 7679 2000

Copyright © 2021 UCL | Disclaimer | Freedom of Information | Accessibility | Privacy | Cookies | Contact Us